性做久久久久久坡多野结衣-性做久久久久久久久浪潮-性欲影院-性影院-国产精品线路一线路二-国产精品兄妹在线观看麻豆

官方微信|手機版

產品展廳

產品求購企業資訊會展

發布詢價單

化工儀器網>產品展廳>試劑標物>行業專用試劑>生化與分子生物學用試劑>LC R5000-50MG 雷帕霉素|Rapamycin|Sirolimus|西羅莫司|現貨原裝

分享
舉報 評價

LC R5000-50MG 雷帕霉素|Rapamycin|Sirolimus|西羅莫司|現貨原裝

參考價 850
訂貨量 ≥1
具體成交價以合同協議為準
  • 公司名稱 上海葉舟生物科技有限公司
  • 品牌 LC Laboratories
  • 型號 LC R5000-50MG
  • 產地 LC R5000 50MG
  • 廠商性質 經銷商
  • 更新時間 2015/8/13 17:51:53
  • 訪問次數 774

聯系我們時請說明是化工儀器網上看到的信息,謝謝!


上海葉舟生物科技有限公司從成立之初就秉著服務科研 , 傳承文明的理念 , 努力為中國廣大生命科學工作者提供Z全面的產品與信息咨詢 。 傳播科技文明 , 服務人類健康一直都是生命科學研究人員奮斗的目標 , 在這個文明的梯隊里 , 我們能為廣大科研工作者提供一些便捷的服務 , 使他們能全身心的投入工作 , 擺脫一些瑣事的煩惱 , 把較大的能量釋放到Z前沿的工作中去 , 為此我們感到十分的欣慰。   浩然生物始終堅持社會效應與公司發展的雙重奉獻 , 嚴格穩定的財務政策確保了我們向科技工作者提供產品與服務的持續性 , 同時浩然生物也和廣大科研工作人員一樣努力的工作 , 在品牌不斷延伸與壯大的同時時刻警醒自己知恩圖報回饋社會的責任。       縮小文明差距 , 擴大科技交流一直是我們的工作指向 , 為此 , 我們時刻關注著世界生命科學的較早動態 , 并努力打造一個相互交流的平臺 , 把優秀的民族產品介紹給世界 , 把 *的技術與資訊帶回中國 , 文明的平衡與和諧是我們永遠追求的目標。同時我們要特別感謝在公司發展的過程當中給過我們很多建議與意見的中國當代的科技工作者,是他們使我們感到了公司必須盡快發展的責任與壓力,我們也要感謝在公司發展過程當中給過我們很多競爭壓力與困難的國內外的生物公司,是他們使我們感到了公司必須居安思危逆流而上,時刻保持創新的思想與大量的行動,努力增強抗擊打與出奇制勝的能力。上海浩然生物技術有限公司隨時歡迎與期待著各位用戶與朋友的批評與建議。

G418,MTT,IPTG,DTT,STZ,ONPG


LC Laboratories相關資料如下:
R-5000 Rapamycin, >99%
M.W. 914.17 C51H79NO13 [53123-88-9]
RTECS:  VE6250000 M.I. 12:  8288 M.I. 14:  8114
Storage:  Store at or below -20 ºC. 
Solubility:  Soluble in DMSO or ethanol (up to about 50 mg/mL for either solvent). 
Disposal:  A
View the MSDS for this product:
• Immunosuppressant, related to FK-506, but without calcineurin inhibitory activity even when complexed to FK-506 binding protein.  Selectively blocks signaling that leads to p70 S6 kinase activation (IC50 = 50 pM).  Terada, N., et al.  "Failure of rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase."  J. Biol. Chem. 268:  12062-12068 (1993).  Fingar, D.C., et al.  "Dissociation of pp70 ribosomal protein S6 kinase from insulin-stimulated glucose transport in 3T3-L1 adipocytes."  J. Biol. Chem. 268:  3005-3008 (1993).  Price, D.J., et al.  "Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase."  Science 257:  973-977 (1992).  Chung, J., et al.  "Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases."  Cell 69:  1227-1236 (1992).
• Lymphokine-induced cell proliferation at the G1 phase is inhibited and apoptosis in a murine B cell line is induced by rapamycin.  Rapamycin arrests the Saccharomyces cerevisiae cell cycle irreversibly in the G1 phase.  Morice, W.G. ,et al.  "Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes."  J. Biol. Chem. 268:  3734-3738 (1993).  Kay, J.E., et al.  "Inhibition of T and B lymphocyte proliferation by rapamycin."  Immunology 72:  544-549 (1991).  Heitman, J., et al.  "Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast."  Science 253:  905-909 (1991).
• Due to a different mechanism of action than cyclosporin and FK506, rapamycin may prove to be important in organ transplant patient therapy.  Fewer side effects than the standard anti-rejection treatments have been observed.  Proliferation of activated T cells, but not apoptosis, is blocked by rapamycin.  The induction of apoptosis of rejection-causing T cells reduces the tendency towards transplant rejection.  Schwarz, C. and Oberbauer, R.  "The future role of target of rapamycin inhibitors in renal transplantation."  Curr Opin Urol. 12:  109-113 (2002).  Wells, A.D. et al.  "Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance."  Nat. Med. 5:  1303-1307 (1999).  Li, Y., et al.  "Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance."  Nat. Med. 5:  1298-1302 (1999).
• We note that one of our competitors, Selleck Chemical, advertises 99.9% purity for its rapamycin.  This claim is not credible in general chemical terms for this complex natural product, nor in terms of available analytical techniques.  Furthermore, we have had Selleck's rapamycin analyzed by a highly experienced and expert clinical analytical laboratory that specializes in rapamycin analyses.  Using liquid chromatography - mass spectrometry, they found a purity of 96.7% (cis plus trans) for a lot of Selleck's rapamycin.  In contrast, we have proven our rapamycin to be greater than 99% in purity for every lot, no exceptions.
• More on the subject of rapamycin purity:  HPLC analysis of rapamycin is somewhat complicated.  Rapamycin forms several chromatographically separable species in solution, consisting perhaps of different conformers, tautomers, hydrates and/or isomers, but they are all in equilibrium with the major form, trans-rapamycin.  We have shown this by collecting the individual impurity peaks in our rapamycin product and individually re-injecting them into the HPLC.  In each case, upon re-injection the collected impurity peak is reduced or absent, and the major peak is again trans-rapamycin, of ~95% purity or higher, thus confirming re-equilibration back to the major trans-isomer of rapamycin.
Because we find that all significant impurities (generally, those above 0.1%) in our product, including the cis-isomer, are in equilibrium with the trans isomer in the solution used for analysis, the actual purity of our product is >99% rapamycin, in all of its equilibrium forms.  In contrast, material from other suppliers typically contains impurities that do not equilibrate with trans-rapamycin, and thus are genuine contaminants.
These results also indicate that it is probably not possible to obtain the trans isomer in pure form, because in solution it will quickly re-equilibrate to the mixture of cis and trans.
• Rapamycin formulations for in vivo use:  Many of our customers have asked for information about preparing formulations of rapamycin for administration to animals.  Here are several journal citations and links for information on this topic:
describes a vehicle for rapamycin injection consisting of a rapamycin suspension in 0.2% carboxymethyl cellulose and 0.25% polysorbate-80.  They don't say how the suspension was done; one way is to thoroughly agitate or grind the rapamycin in the vehicle.  Another way, probably better and easier, is to dissolve the rapamycin at high concentration in DMSO, dimethylformamide or dimethylacetamide, then dilute into the aqueous vehicle--this should give a very fine suspension if agitation is good during addition of the DMSO solution.  Injection was i.m.  Gallo, R., et al.  "Inhibition of Intimal Thickening After Balloon Angioplasty in Porcine Coronary Arteries by Targeting Regulators of the Cell Cycle."  Circulation 99:  2164-2170 (1999).
describes a similar protocol; these workers dissolved the rapamycin in dimethylacetamide, then added it in 1:24 proportion to a vehicle of (final conc.'s) 10% polyethylene glycol (MW avg. = 400) and 17% polyoxyethylene sorbitan monooleate.  Injection was i.p. in mice, total vol. of 100 µl.  Rivera, V.M., et al.  "Long-term regulated expression of growth hormone in mice after intramuscular gene transfer."  Proc. Natl. Acad. Sci. USA 96:  8657-8662 (1999).
 used 0.75 mg/kg rapamycin in 5% dimethyl sulfoxide, for injection into pigs via jugular vein catheter.  Kimball, S.R., et al.  "Feeding stimulates protein synthesis in muscle and liver of neonatal pigs through an mTOR-dependent process."  Am. J. Physiol. Endocr. Metab. 279:  E1080-E1087 (2000).
 injected rapamycin in 51% wt/vol polyethylene glycol 300 (PEG300), 2.5% wt/vol polysorbate 80, 10% vol/vol ethanol, i.p.  Hackstein, H., et al.  "Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells."  Blood 100:  1084-1087 (2002).
 injected rapamycin i.p. in mice by diluting an ethanol stock solution of rapamycin first into sterile 10% PEG400/8% ethanol and then that solution was further diluted into an equal volume of sterile 10% Tween 80 for a final concentration of 20 µg rapamycin/100 µl.  (Most of this information is in the Materials and Methods section of the paper, but the "ethanol stock solution" is mentioned under the Cell Culture and Antibodies section, and the additional details are found in the Regrowth Delay Assay section.)  Eshleman, J.S., et al.  "Inhibition of the Mammalian Target of Rapamycin Sensitizes U87 Xenografts to Fractionated Radiation Therapy"  Cancer Res. 62:  7291-7297 (2002).
• The solubility of rapamycin in 50/50 DMSO/water, as used in osmotic pumps, is about 0.5 mg/mL at ambient temperature.
• Quantitation of rapamycin, metabolites and related compounds such as everolimus and FK-506 in blood, tissues and other matrices is offered as a service by Rocky Mountain Labs (Rocky Mountain Labs).  This firm is not affiliated with LC Labs.
• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
• Please see also our other standard immunosuppressant products:

品名 中文名: 雷帕霉素;西羅莫司
英文名: Sirolimus;Rapamycin
 雷帕霉素(Rapmnycin)是從吸水鏈霉菌Streptomyces hygroscopicus中分離出來的三烯大環內酯類抗生素,它是一種新型高效免疫抑制劑,同時又是一種有效的抗真菌劑并具有抗腫瘤的作用。
抑制原理:可能通過阻斷IL-2啟動的T細胞增殖而選擇性抑制T細胞,用于抗移植排斥反應。
產地 貨號 規格 單價 備注 產品說明書
雷帕霉素Rapamycin  LC R5000 50MG 850

雷帕霉素Rapamycin  LC R5000 100MG   1380
 



化工儀器網

采購商登錄
記住賬號    找回密碼
沒有賬號?免費注冊

提示

×

*您想獲取產品的資料:

以上可多選,勾選其他,可自行輸入要求

個人信息:

溫馨提示

該企業已關閉在線交流功能

主站蜘蛛池模板: 肇庆市| 永年县| 当涂县| 眉山市| 分宜县| 新邵县| 乐平市| 中超| 通海县| 舟曲县| 工布江达县| 竹北市| 仁寿县| 海阳市| 泸西县| 阿克| 安徽省| 泽普县| 镇雄县| 搜索| 阳江市| 泽普县| 龙南县| 瓦房店市| 克山县| 正阳县| 平乐县| 剑阁县| 平陆县| 岳池县| 沙坪坝区| 新乡市| 威远县| 衡阳市| 含山县| 柏乡县| 古交市| 丰都县| 台北市| 个旧市| 射洪县|